Compare AbCellera Biologics Inc (ABCL) vs Celestica Inc (CLS) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Celestica (CLS) trades at $350.20, up 4.16% over 24 hours, with a bearish technical signal and neutral oscillators. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and robust profitability metrics, including a 52.45% ROE. Recent leadership appointments in cloud solutions and positive analyst coverage highlight growth potential amid competitive pressures.

The stock presents a compelling growth opportunity with a consensus price target of $440.10, implying 25% upside, supported by AI and data center demand. Key risks include margin pressures, technical bearish signals, and reliance on execution amid industry competition. Investors should weigh strong earnings trajectory against near-term volatility.